Enzo Biochem, Inc. (ENZ)
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
$57.12M
Mr. Hamid Erfanian
465.00
New York, NY
Jun 13, 1980
-3.17
$-0.35
2.87
3.50
76.62%
947.53%
1.31
-0.00
0.85
12.43
3.16
47.86%
61.16%
Similar stocks (9)
Sotera Health Company
SHC
Castle Biosciences, Inc.
CSTL
Biodesix, Inc.
BDSX
Sera Prognostics, Inc.
SERA
FONAR Corporation
FONR
Exagen Inc.
XGN
DarioHealth Corp.
DRIO
Neuronetics, Inc.
STIM
Psychemedics Corporation
PMD
ETF Exposure (13)
iShares Micro-Cap ETF
IWC
0.01284%
Dimensional U.S. Targeted Value ETF
DFAT
9.051399999999999e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
2.2032e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (9)
Sotera Health Company
SHC
Castle Biosciences, Inc.
CSTL
Biodesix, Inc.
BDSX
Sera Prognostics, Inc.
SERA
FONAR Corporation
FONR
Exagen Inc.
XGN
DarioHealth Corp.
DRIO
Neuronetics, Inc.
STIM
Psychemedics Corporation
PMD
ETF Exposure (13)
iShares Micro-Cap ETF
IWC
0.01284%
Dimensional U.S. Targeted Value ETF
DFAT
9.051399999999999e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
2.2032e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%